TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Update

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 57,400 shares, a decrease of 56.3% from the May 15th total of 131,200 shares. Based on an average trading volume of 4,670,000 shares, the days-to-cover ratio is currently 0.0 days.

TC Biopharm Trading Down 5.3 %

NASDAQ:TCBP traded down $0.06 during mid-day trading on Thursday, reaching $1.06. 35,784 shares of the company were exchanged, compared to its average volume of 3,082,180. TC Biopharm has a 12 month low of $0.85 and a 12 month high of $19.60. The company has a fifty day moving average of $1.33 and a 200 day moving average of $2.04. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.31.

TC Biopharm (NASDAQ:TCBP) last released its earnings results on Wednesday, May 15th. The company reported ($2.80) earnings per share (EPS) for the quarter.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.